| Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis TPC Dorlo, M Balasegaram, JH Beijnen, PJ de Vries Journal of Antimicrobial Chemotherapy 67 (11), 2576-2597, 2012 | 839 | 2012 |
| Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance S Rijal, B Ostyn, S Uranw, K Rai, NR Bhattarai, TPC Dorlo, JH Beijnen, ... Clinical Infectious Diseases 56 (11), 1530-1538, 2013 | 359 | 2013 |
| Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients TPC Dorlo, PPAM van Thiel, ADR Huitema, RJ Keizer, HJC de Vries, ... Antimicrobial agents and chemotherapy 52 (8), 2855-2860, 2008 | 198 | 2008 |
| Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure TPC Dorlo, S Rijal, B Ostyn, PJ de Vries, R Singh, N Bhattarai, S Uranw, ... The Journal of infectious diseases 210 (1), 146-153, 2014 | 159 | 2014 |
| LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014 J Blum, P Buffet, L Visser, G Harms, MS Bailey, E Caumes, J Clerinx, ... Journal of travel medicine 21 (2), 116-129, 2014 | 132 | 2014 |
| Optimal dosing of miltefosine in children and adults with visceral leishmaniasis TPC Dorlo, ADR Huitema, JH Beijnen, PJ de Vries Antimicrobial agents and chemotherapy 56 (7), 3864-3872, 2012 | 127 | 2012 |
| Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trial M Wasunna, S Njenga, M Balasegaram, N Alexander, R Omollo, ... PLoS neglected tropical diseases 10 (9), e0004880, 2016 | 90 | 2016 |
| Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia B Ostyn, E Hasker, TPC Dorlo, S Rijal, S Sundar, JC Dujardin, M Boelaert PloS one 9 (6), e100220, 2014 | 89 | 2014 |
| Safety and efficacy of single dose versus multiple doses of AmBisome® for treatment of visceral leishmaniasis in Eastern Africa: a randomised trial EAG Khalil, T Weldegebreal, BM Younis, R Omollo, AM Musa, W Hailu, ... PLoS neglected tropical diseases 8 (1), e2613, 2014 | 87 | 2014 |
| Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples AE Kip, KC Kiers, H Rosing, JHM Schellens, JH Beijnen, TPC Dorlo Journal of pharmaceutical and biomedical analysis 135, 160-166, 2017 | 84 | 2017 |
| Clinical pharmacokinetics of systemically administered antileishmanial drugs AE Kip, JHM Schellens, JH Beijnen, TPC Dorlo Clinical pharmacokinetics 57 (2), 151-176, 2018 | 75 | 2018 |
| Systematic review of biomarkers to monitor therapeutic response in leishmaniasis AE Kip, M Balasegaram, JH Beijnen, JHM Schellens, PJ de Vries, ... Antimicrobial agents and chemotherapy 59 (1), 1-14, 2015 | 72 | 2015 |
| Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East … R Omollo, N Alexander, T Edwards, EAG Khalil, BM Younis, AA Abuzaid, ... Trials 12, 1-10, 2011 | 68 | 2011 |
| Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography–tandem mass spectrometry TPC Dorlo, MJX Hillebrand, H Rosing, TA Eggelte, PJ de Vries, ... Journal of Chromatography B 865 (1-2), 55-62, 2008 | 68 | 2008 |
| Pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis MM Castro, MA Gomez, AE Kip, A Cossio, E Ortiz, A Navas, TPC Dorlo, ... Antimicrobial agents and chemotherapy 61 (3), 10.1128/aac. 02198-16, 2017 | 61 | 2017 |
| Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation JB Langenhorst, TPC Dorlo, EM van Maarseveen, S Nierkens, J Kuball, ... Clinical pharmacokinetics 58, 627-637, 2019 | 58 | 2019 |
| Characterization and identification of suspected counterfeit miltefosine capsules TPC Dorlo, TA Eggelte, PJ de Vries, JH Beijnen Analyst 137 (5), 1265-1274, 2012 | 58 | 2012 |
| Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults P Byakika-Kibwika, M Lamorde, V Okaba-Kayom, H Mayanja-Kizza, ... Journal of antimicrobial chemotherapy 67 (5), 1217-1223, 2012 | 57 | 2012 |
| Pharmacokinetics, safety, and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase II … J Mbui, J Olobo, R Omollo, A Solomos, AE Kip, G Kirigi, P Sagaki, ... Clinical Infectious Diseases 68 (9), 1530-1538, 2019 | 53 | 2019 |
| Severe encephalopathy and polyneuropathy induced by dichloroacetate D Brandsma, TPC Dorlo, JH Haanen, JH Beijnen, W Boogerd Journal of neurology 257, 2099-2100, 2010 | 53 | 2010 |
Boelaert MProfessor of Epidemiology and Control of Neglected Tropical Diseases, Institute of Tropical Medicine在 itg.be 的电子邮件经过验证
